RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,915,842 | +39.0% | 345,293 | 0.0% | 2.42% | +142.5% |
| Q2 2023 | $5,693,882 | -7.6% | 345,293 | 0.0% | 1.00% | -21.5% |
| Q1 2023 | $6,160,027 | -38.7% | 345,293 | 0.0% | 1.27% | -41.2% |
| Q4 2022 | $10,054,932 | +18.9% | 345,293 | 0.0% | 2.16% | +9.7% |
| Q3 2022 | $8,460,000 | +490.4% | 345,293 | 0.0% | 1.97% | +416.5% |
| Q2 2022 | $1,433,000 | -64.0% | 345,293 | 0.0% | 0.38% | -61.8% |
| Q1 2022 | $3,978,000 | +15.4% | 345,293 | 0.0% | 1.00% | +49.6% |
| Q4 2021 | $3,446,000 | -12.1% | 345,293 | +15.0% | 0.67% | +8.8% |
| Q3 2021 | $3,922,000 | -33.3% | 300,293 | 0.0% | 0.62% | -15.3% |
| Q2 2021 | $5,880,000 | +37.5% | 300,293 | +49.4% | 0.73% | -8.0% |
| Q1 2021 | $4,276,000 | -28.5% | 201,046 | 0.0% | 0.79% | +31.3% |
| Q4 2020 | $5,977,000 | +17.4% | 201,046 | -14.4% | 0.60% | -57.6% |
| Q3 2020 | $5,089,000 | -17.4% | 234,846 | -15.0% | 1.42% | -28.4% |
| Q2 2020 | $6,161,000 | +46.5% | 276,289 | 0.0% | 1.98% | -18.1% |
| Q1 2020 | $4,205,000 | – | 276,289 | – | 2.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |